A tin precursor for the synthesis of no-carrier-added [I]MIBG and [211At]MABG

Radioiodinated MIBG has shown considerable promise as an imaging agent for cardiac and oncologic applications, and also as a targeted radiotherapeutic for treating patients with neuroendocrine tumors. This radiolabeled agent, synthesized at a no‐carrier‐added level, has demonstrated advantages over...

Full description

Saved in:
Bibliographic Details
Published in:Journal of labelled compounds & radiopharmaceuticals Vol. 50; no. 3; pp. 177 - 182
Main Authors: Vaidyanathan, Ganesan, Affleck, Donna J., Alston, Kevin L., Zalutsky, Michael R.
Format: Journal Article
Language:English
Published: Chichester, UK John Wiley & Sons, Ltd 15-03-2007
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radioiodinated MIBG has shown considerable promise as an imaging agent for cardiac and oncologic applications, and also as a targeted radiotherapeutic for treating patients with neuroendocrine tumors. This radiolabeled agent, synthesized at a no‐carrier‐added level, has demonstrated advantages over the carrier‐added preparation in preliminary clinical studies. Earlier we developed a silicon precursor from which both radioiodinated MIBG and the α‐particle‐emitting 211At analog [211At]MABG could be synthesized at a no‐carrier‐added level. In order to increase the practicality of this approach, we have developed a synthesis of a tin precursor in two steps from a readily available starting material. This tin precursor, N, N′‐bis(tert‐butyloxycarbonyl)‐3‐(trimethylstannyl)benzylguanidine (Bis‐Boc MTMSBG) was evaluated for the synthesis of n.c.a. [*I]MIBG and [211At]MABG via halodestannylation. The radiochemical yields were 83 ± 9% (n=7), 30 ± 21% (n=2), 77 ± 2% (n=2), and 66 ± 7% (n=4) for labeling with 131I, 124I, 125I, and 211At, respectively. Copyright © 2007 John Wiley & Sons, Ltd. No‐carrier‐added [*I]MIBG and [211At]MABG were synthesized from a tin precursor, the guanidine group of which was protected with Boc groups. Copyright © 2007 John Wiley & Sons, Ltd.
Bibliography:ArticleID:JLCR1243
National Institutes of Health - No. CA78417, CA93371
Pediatric Brain Foundation
ark:/67375/WNG-5CNHTVVP-6
istex:E1B7EEFB162DB192124E6C1DD700EF054DB2F58F
ISSN:0362-4803
1099-1344
DOI:10.1002/jlcr.1243